BPC-157 and the tissue-repair evidence base — what the clinical literature actually shows.

BPC-157 occupies the unusual position of carrying a substantive preclinical evidence base — gastrointestinal repair, tendon and ligament healing, vascular and neural effects in animal models — alongside a clinical literature that is real but markedly smaller and uneven in quality. Practitioners who frame it precisely treat it as an evidence-supported adjunct in defined contexts, not as a generalised regenerative agent. The regulatory posture varies materially across SEA: some markets treat it as a research compound, others as a compounded peptide accessible through specific clinical channels, others as out-of-scope entirely. The honest practitioner conversation is about evidence quality, regulatory channel, and protocol context — not about marketed promise. This article summarises the clinical literature as it stands in 2026 and notes the open questions worth tracking.